Study of Lademirsen (SAR339375) in Patients With Alport Syndrome (HERA)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02855268 |
|
Recruitment Status :
Terminated
(The results of the futility analysis led to the study termination. No unexpected safety findings were identified.)
First Posted : August 4, 2016
Last Update Posted : October 17, 2022
|
Sponsor:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
Sanofi ( Genzyme, a Sanofi Company )
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Primary Objectives:
- To assess the efficacy of lademirsen (SAR339375) in reducing the decline in renal function
- To assess the safety and tolerability of lademirsen (SAR339375) in subjects with Alport syndrome
Secondary Objectives:
- To assess plasma pharmacokinetic (PK) parameters of the parent compound and its metabolites
- To assess the potential formation of anti-drug antibodies (ADAs) following administration of lademirsen (SAR339375)
- To assess the pharmacodynamic effect of lademirsen (SAR339375) on miR-21 and on changes in renal injury and function biomarkers.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Alport's Syndrome | Drug: lademirsen (SAR339375) Drug: Placebo | Phase 2 |
The planned length of participation in the study for each subject is up to approximately 110 weeks (from screening through completion of follow-up). This includes:
- Screening/baseline period of up to 4 weeks
- Double-blind, placebo-controlled treatment period of 48 weeks
- Open-label extension treatment period of 48 weeks ( all subject to enter a 48-week open label extension period and receive active treatment with lademirsen (SAR339375))
- Post-treatment follow-up period of 10 weeks
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 43 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Care Provider, Investigator) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of Lademirsen (SAR339375) for Subcutaneous Injection Administered Every Week in Patients With Alport Syndrome |
| Actual Study Start Date : | November 2, 2019 |
| Actual Primary Completion Date : | September 22, 2022 |
| Actual Study Completion Date : | September 22, 2022 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Alport syndrome
| Arm | Intervention/treatment |
|---|---|
|
Experimental: lademirsen (SAR339375)
Eligible participants will receive subcutaneous injection every week for 48 weeks
|
Drug: lademirsen (SAR339375)
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection |
|
Placebo Comparator: Placebo
Eligible participants will receive subcutaneous injection every week for 48 weeks
|
Drug: Placebo
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous injection |
Primary Outcome Measures :
- Number of participants with adverse events [ Time Frame: Baseline to maximum 106 weeks ]Number of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
- Annualized change in estimated glomerular filtration rate eGFR from baseline [ Time Frame: Baseline to 48 weeks ]Annualized change in estimated glomerular filtration rate eGFR from baseline to 48 weeks
Secondary Outcome Measures :
- Pharmacokinetics (PK) : Maximum concentration in plasma (Cmax) [ Time Frame: 24 weeks and 48 weeks ]Plasma concentrations (Cmax) of lademirsen (SAR339375), RG0005, and sum of lademirsen (SAR339375) and RG0005 (SUM)
- Pharmacokinetics (PK) : Trough plasma concentration (Ctrough) [ Time Frame: 24 weeks, 48 weeks and 96 weeks ]Plasma concentrations (Ctrough) of sum of lademirsen (SAR339375) and RG0005 (SUM)
- Number of participants with anti-drug antibodies (ADAs) [ Time Frame: Baseline to maximum 106 weeks ]Number of participants with ADAs incidents and titer
- Number of participant with adverse events associated to ADAs [ Time Frame: Baseline to maximum 106 weeks ]Association of ADAs with adverse events per participants will be collected.
- Percent change in eGFR values [ Time Frame: Baseline to 24 weeks, 48 weeks and 96 weeks ]Percent change in eGFR values from baseline to 24 weeks and 48 weeks
- Proportion of subjects who reach end staged renal disease (ESRD) [ Time Frame: Baseline to 48 weeks ]Proportion of participants who reach ESRD as defined by an eGFR ≤15 mL/min/1.73 m^2 or initiation of hemodialysis or renal transplantation from baseline to 48 weeks
- Proportion of subjects with a reduction from baseline in eGFR [ Time Frame: Baseline to Weeks 24, 48, and 96 ]Proportion of subjects with a reduction from baseline in eGFR of <10%, <20%, <30%, or <40% reduction at Week 24, 48 and 96
- Change in circulating miR-21 [ Time Frame: Weeks 24, 48, and 96 ]Change of circulating miR-21 from baseline to 24 weeks, 48 weeks and 96 weeks
- Change in blood urea nitrogen [ Time Frame: Baseline to Weeks 24, 48, and 96 ]Change in blood urea nitrogen from baseline to 24 weeks, 48 weeks and 96 weeks
- Change in protein/creatinine ratio and albumin/creatinine ratio in urine only [ Time Frame: Baseline to Weeks 24, 48, and 96 ]Change in protein/creatinine ratio and albumin/creatinine ratio in urine only from baseline to 24 weeks, 48 weeks and 96 weeks
- Change in epidermal growth factor (EGF) in urine only [ Time Frame: Baseline to Weeks 24, 48, and 96 ]Change in EFG from baseline to 24 weeks, 48 weeks and 96 weeks
- Change in creatinine in both blood and urine [ Time Frame: Baseline to Weeks 24, 48, and 96 ]Change in ceatinine from baseline to 24 weeks, 48 weeks and 96 weeks
- Change in Cystatin C in both blood and urine [ Time Frame: Baseline to Weeks 24, 48, and 96 ]Change in Cystatin C from baseline to 24 weeks, 48 weeks and 96 weeks
- Change in transforming growth factor-β (TGF-β) in both blood and urine [ Time Frame: Baseline to Weeks 24, 48, and 96 ]Change in TGF-β from baseline to 24 weeks, 48 weeks and 96 weeks
- Change in neutrophil gelatinase-associated lipocalin (NGAL) in both blood and urine [ Time Frame: Baseline to Weeks 24, 48, and 96 ]Change in NGAL from baseline to 24 weeks, 48 weeks and 96 weeks
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 55 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion criteria :
- Male or female
-
Confirmed diagnosis of Alport syndrome
- Clinical diagnosis (hematuria, family history, hearing loss, ocular change), AND
- Genetic confirmation of Alport Syndrome in the subject or the family member, OR
- Kidney biopsy showing glomerular basement membrane abnormalities (eg, significant thinning, thickening, irregularity or lucencies) consistent with Alport Syndrome.
- Age 18-55 years old
- eGFR > 35 ml/min/1.73m^2 and <90 mL/min/1.73m^2 (based on CKD-EPI) at screening
-
Renal Function Criteria (patients must meet at least one of the following CRITERIA A, B or C):
- A)Decline in eGFR of ≥4 mL/min/1.73 m^2/year (eGFR slope <= -4) based on a linear regression slope analysis of ≥4 eGFR measurements within 3 years prior to the study and with a minimum of 2-year time span (the last, of the screening measurement, and first eGFR measurements should be separated by at least 2 years). eGFR should be calculated by using either the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation.
- B) proteinuria (UPCR) >2000 mg/g (UACR>1000 mg/g)
- C) Age and sex adjusted eGFR (based on CKD-Epi; male 18-23 eGFR<90 mL/min/1.73m^2
- ACE inhibitor and/or ARB, the dosing regimen should be stable for at least 30 days prior to screening
- Sexually active female subjects of childbearing potential and sexually mature male subjects must agree to practice true abstinence in line with their preferred and usual lifestyle or to use two acceptable effective methods of contraception for the entire duration of the study and for at least 6 weeks after last dose.
- Negative drug screen for opiates, cocaine, heroin, phencyclidine, amphetamines (including ecstasy), barbiturates, benzodiazepines, and cannabinoids. At the Investigator's discretion, subjects prescribed benzodiazepines, cannabinoids, or opiates with positive results on a drug screen may be allowed.
- Negative screening results for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, and human immunodeficiency virus (HIV) antibody
- Normal biological tests
- Able to understand all study procedures in the informed consent form (ICF) and willing to comply with all aspects of the protocol
Exclusion criteria:
- Causes of chronic kidney disease aside from Alport syndrome (including but not limited to other heritable disorders leading to chronic kidney disease, diabetic nephropathy, hypertensive nephropathy, lupus nephritis, IgA nephropathy)
- ESRD as evidenced by ongoing dialysis therapy or history of renal transplantation
- Any clinically significant illness within 30 days before screening or surgical or medical condition (other than Alport syndrome) that could interfere with the subject's study compliance; confound the study results; impact subject safety; or significantly alter the absorption, distribution, metabolism, or excretion of drugs.
- Weight > 110 kg
- Any history of active malignancy within the last 1 year (history of localized basal cell or squamous cell carcinoma and cervical carcinoma in situ that has been excised/appropriately treated or a fully excised malignant lesion with a low probability of recurrence will not be considered exclusionary)
- Prior treatment with Bardoxolone within 90 days prior to screening
- History or presence of alcoholism or drug abuse within 2 years before screening or other concurrent social conditions that would potentially interfere with the subject's study compliance, at the discretion of the Investigator
- Participation in a recent investigational study and receipt of an investigational drug or investigational use of a licensed drug within 30 days or 5 half lives, whichever is longer, prior to screening
- History or presence of hypersensitivity or idiosyncratic, allergic, or other clinically significant reaction to the study drug (including placebo), inactive ingredients, or related compounds (eg, other oligonucleotide products)
- Any other condition or circumstance that, in the opinion of the Investigator, may make the subject unlikely to complete the study or comply with study procedures and requirements, or may pose a risk to the subject's safety and well-being
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02855268
Locations
Show 23 study locations
Sponsors and Collaborators
Genzyme, a Sanofi Company
Investigators
| Study Director: | Clinical Sciences & Operations | Sanofi |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Genzyme, a Sanofi Company |
| ClinicalTrials.gov Identifier: | NCT02855268 |
| Other Study ID Numbers: |
ACT16248 2019-004394-10 ( EudraCT Number ) |
| First Posted: | August 4, 2016 Key Record Dates |
| Last Update Posted: | October 17, 2022 |
| Last Verified: | October 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Sanofi ( Genzyme, a Sanofi Company ):
|
Kidney disease Nephritis Hereditary nephritis Hereditary kidney disease |
Additional relevant MeSH terms:
|
Nephritis, Hereditary Syndrome Disease Pathologic Processes Urogenital Abnormalities Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases |
Nephritis Kidney Diseases Urologic Diseases Male Urogenital Diseases Congenital Abnormalities Collagen Diseases Connective Tissue Diseases |